• Mineralys Therapeutics presented late-breaking ENDO 2026 data from a post hoc proteomic analysis of lorundrostat in uncontrolled hypertension.
• The analysis showed reductions in several biomarkers linked to future heart-failure risk, supporting a potential disease-modifying signal beyond blood-pressure control.
• Findings also pointed to coordinated shifts consistent with less fibrosis, reinforcing the rationale to study lorundrostat in heart failure.
• Lorundrostat is under FDA review, with a PDUFA target date of December 22, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606141000PRIMZONEFULLFEED9746327) on June 14, 2026, and is solely responsible for the information contained therein.